Hormone receptor (HR)-positive, human epidermal growth factor receptor 2(HER2)-negative early breast cancer accounts for nearly 70% of all breast cancers and generally has a favorable prognosis (Giaquinto et al., 2022). The gene discussed is NR4A1; the disease is breast cancer.